BRPI0807083A2 - Eficácia aumentada de compostos de fármaco de alilamina - Google Patents

Eficácia aumentada de compostos de fármaco de alilamina

Info

Publication number
BRPI0807083A2
BRPI0807083A2 BRPI0807083-0A BRPI0807083A BRPI0807083A2 BR PI0807083 A2 BRPI0807083 A2 BR PI0807083A2 BR PI0807083 A BRPI0807083 A BR PI0807083A BR PI0807083 A2 BRPI0807083 A2 BR PI0807083A2
Authority
BR
Brazil
Prior art keywords
drug compounds
increased efficacy
allylamine drug
allylamine
efficacy
Prior art date
Application number
BRPI0807083-0A
Other languages
English (en)
Inventor
Pichit Suvanprakorn
Nardo Zaias
Panida Vayumhasuwan
Original Assignee
Biophile Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophile Corp Ltd filed Critical Biophile Corp Ltd
Publication of BRPI0807083A2 publication Critical patent/BRPI0807083A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0807083-0A 2007-02-05 2008-02-05 Eficácia aumentada de compostos de fármaco de alilamina BRPI0807083A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89943307P 2007-02-05 2007-02-05
PCT/US2008/001492 WO2008097530A1 (en) 2007-02-05 2008-02-05 Increased effectiveness of allylamine drug compounds

Publications (1)

Publication Number Publication Date
BRPI0807083A2 true BRPI0807083A2 (pt) 2015-05-26

Family

ID=39676720

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807083-0A BRPI0807083A2 (pt) 2007-02-05 2008-02-05 Eficácia aumentada de compostos de fármaco de alilamina

Country Status (6)

Country Link
US (5) US8052984B2 (pt)
EP (2) EP2124878B1 (pt)
CN (2) CN101652124A (pt)
BR (1) BRPI0807083A2 (pt)
CA (1) CA2676975A1 (pt)
WO (1) WO2008097530A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124878B1 (en) * 2007-02-05 2015-09-02 Biophile Corporation, Ltd Increased effectiveness of allylamine drug compounds
WO2008121709A1 (en) * 2007-03-30 2008-10-09 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
RU2527894C2 (ru) 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
CA2731455A1 (en) * 2008-07-23 2010-01-28 Gregor Cevc Methods of administering topical antifungal formulations for the treatment of fungal infections
WO2010086726A1 (en) * 2009-01-30 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions for nail and skin treatment
WO2011019317A1 (en) * 2009-08-13 2011-02-17 Moberg Derma Ab Compositions and methods for treating fungal infection of the nail
FR2954163B1 (fr) * 2009-12-18 2012-03-16 Galderma Pharma Sa Utilisation d'un tensioactif cationique, avantageu-sement amphotere, pour la preparation d'une composition antifongique applicable sur l'ongle
GB2478159A (en) * 2010-02-26 2011-08-31 Lrc Products Composition for the treatment of fungal nail infection
AU2012215383B2 (en) * 2011-02-11 2016-06-09 Moberg Pharma Ab Novel antifungal composition
EP2572720A1 (en) * 2011-09-21 2013-03-27 Elzbieta Cosmetics B.V. Formulation and treatment for acne
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US20180343479A1 (en) * 2017-05-26 2018-11-29 Opentv, Inc. Universal optimized content change
KR102060421B1 (ko) 2018-03-15 2019-12-30 서울대학교산학협력단 난용성 항진균제가 봉입된 왁스 오일 비드 및 이의 제조방법
CN111436428A (zh) * 2020-05-18 2020-07-24 兰州大学 萘苄胺类抗真菌药物在防治农业病害中的用途
EP4161490A1 (en) * 2020-06-03 2023-04-12 The Materia Company Limited Stable formulation of efinaconazole
KR20230116911A (ko) 2020-12-08 2023-08-04 모베르그 파르마 아베 알릴아민 항진균 조성물을 사용한 조갑진균증의 치료 요법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2673537B1 (fr) * 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5885260A (en) 1991-05-30 1999-03-23 Mehl, Sr.; Thomas L. Freeze-dried liposome delivery system for application of skin treatment agents
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
EP0872229A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
BR0109603A (pt) 2000-03-27 2004-02-25 Schott Glas Novas composições cosméticas, de higiene pessoal, agente de limpeza e de suplemento nutricional e métodos para fabricar e utilizar as mesmas
WO2003030818A2 (en) * 2001-10-05 2003-04-17 Pichit Suvanprakorn Active agents using liposome beads
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
US7135194B2 (en) 2002-09-27 2006-11-14 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
DE10254214A1 (de) 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US20050244522A1 (en) * 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US20060024243A1 (en) * 2004-08-02 2006-02-02 Agis Industries (1983) Ltd. Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
EP2124878B1 (en) * 2007-02-05 2015-09-02 Biophile Corporation, Ltd Increased effectiveness of allylamine drug compounds
JP2010519288A (ja) 2007-02-21 2010-06-03 パワー ペイパー リミテッド イオン導入法のためのテルビナフィン製剤
CA2731455A1 (en) * 2008-07-23 2010-01-28 Gregor Cevc Methods of administering topical antifungal formulations for the treatment of fungal infections

Also Published As

Publication number Publication date
US9216159B2 (en) 2015-12-22
CA2676975A1 (en) 2008-08-14
EP2124878A1 (en) 2009-12-02
US8052984B2 (en) 2011-11-08
EP2526928A1 (en) 2012-11-28
US20150017234A1 (en) 2015-01-15
US20160106845A1 (en) 2016-04-21
EP2124878B1 (en) 2015-09-02
US10471024B2 (en) 2019-11-12
US20120087974A1 (en) 2012-04-12
EP2526928B1 (en) 2018-12-26
US20080188568A1 (en) 2008-08-07
EP2124878A4 (en) 2010-03-17
US8853280B2 (en) 2014-10-07
CN105125529A (zh) 2015-12-09
CN101652124A (zh) 2010-02-17
US20170119700A1 (en) 2017-05-04
WO2008097530A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
EP2124878A4 (en) INCREASED EFFICIENCY OF ALLYLAMINE MEDICINAL COMPOUNDS
DK2041139T3 (da) Farmaceutiske forbindelser
LTC2140867I2 (lt) Farmacinė kompozicija
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0821831A2 (pt) Compostos inseticidas
SMT201600259B (it) Composizioni farmaceutiche antibatteriche
BRPI0917369A2 (pt) Compostos inseticidas
BRPI0918500A2 (pt) compostos inseticidas
BRPI0917188A2 (pt) Compostos inseticidas
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0721651A2 (pt) Composição farmacêutica
HUE071237T2 (hu) Fabry-kór kezelési lehetõségei
JP2008539179A5 (ja) 殺虫活性物質併用の組み合わせ
HUE037800T2 (hu) Gyógyszerkészítmény ektoparaziták leküzdésére
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0820677A2 (pt) Misturas de compostos pesticidas
DK2185142T3 (da) Antiseptiske midler
BRPI0813670A2 (pt) Compostos para tratamento
DK2120884T3 (da) Farmaceutisk sammensætning
BRPI0815670A2 (pt) Inseticidas
DK2235041T3 (da) Antimikrobielle forbindelser
EP2041108A4 (en) 4-HYDROXYTHIOZENZAMIDE DERIVATIVES OF MEDICAMENTS
FI20065388L (fi) Betuliiniperäiset yhdisteet antimikrobisina aineina
PT2209464E (pt) Composição farmacêutica antimalárica
DK2271618T3 (da) Farmaceutiske forbindelser

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL